TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing T cell receptor therapies for cancer patients, with a focus on solid tumors. The lead product candidate, gavo-cel, is being tested in a phase I/II clinical trial for NSCLC, ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The company is also developing TRuC-T cells, such as TC-510 and TC-520 for solid tumors.